Cancer Network
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast CancerReal-World Evidence in NSCLC Guides Clinical Decisions Register: Recent Advances in the Treatment of Multiple Myeloma: Highlights from the IMS 2022 Meeting and BeyondTargeting NSCLC with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsMorning RoundsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Register: Recent Advances in the Treatment of Multiple Myeloma: Highlights from the IMS 2022 Meeting and Beyond
  • Targeting NSCLC with Uncommon EGFR Mutations
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.

Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box

In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.

EP. 1: Third-Line Treatment Data for HER2+ Advanced Breast Cancer

August 12th 2021

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

EP. 2: HER2+ Advanced Breast Cancer: Selecting Third-Line Therapy

August 13th 2021

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

EP. 3: Experts Discuss Third-line Treatment Options for HER2-Positive Advanced Breast Cancer

November 8th 2021

“We’ve been spoiled by 2 extraordinary experiences [in this setting]. Both tucatinib and trastuzumab deruxtecan are much better than anything we’ve had since we got pertuzumab for first-line therapy.” —SARA A. HURVITZ, MD, FACP